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Abstract
Background: Large-cell neuroendocrine carcinoma (LCNEC) of the bile duct is extremely rare and is a high-grade
type of neuroendocrine tumor with an aggressive clinical course. Here, we report a case of LCNEC of the
extrahepatic bile duct.
Case presentation: An 80-year-old man presented with severe jaundice. Endoscopic retrograde cholangiography
and enhanced computed tomography revealed complete obstruction of the common bile duct (CBD) by a dense
tumor measuring 1.5 cm in diameter. Although there were no malignant cells in the biliary brush cytology, we
suspected a cholangiocarcinoma and performed extrahepatic bile duct resection. Histologically, the LCNEC
occupied most of the places deeper than the stratum submucosum and an adenocarcinoma component,
approximately 15%, was present in the mucosa. There were no transitional areas between the two components.
Immunohistochemically, the LCNEC cells were reactive for CD56 and synaptophysin and had a high MIB-1 index
(72%). The patient died of multiple liver, lung, and peritoneal metastases 3 months after surgery.
Conclusions: LCNEC of the CBD is particularly rare and has a very poor prognosis. Only five cases have been
reported in the literature; therefore, there is no established effective therapy, including surgery, for LCNEC of the
CBD at present. An accumulation of additional cases and further studies of multimodal treatment are required in
the future to improve the prognosis.
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Background
Primary neuroendocrine carcinoma (NEC) of the com-
mon bile duct is rare, and only 27 cases have been
reported in the literature so far. One type of NEC, large-
cell neuroendocrine carcinoma (LCNEC), is particularly
rare, and only five cases have been previously reported.
Here, we report a case of LCNEC of the extrahepatic bile
duct and a review of the literature.
Case presentation
An 80-year-old man presented to our hospital with an-
orexia and jaundice that had been present for several
weeks. The patient had neither abdominal tenderness
nor a palpable mass in the right upper quadrant of the
abdomen. He underwent endoscopic submucosal dissec-
tion for multiple early gastric cancers 1 year ago, and all
of the lesions were resected radically. He had severe
chronic obstructive pulmonary disease because of long-
term smoking. The patient’s main occupation was in
agriculture, and he had never worked in the printing or
staining industries. The patient had no family history of
cancer.
On the day of admission, his complete blood count and
serum biochemical parameters were as follows: white
blood cells, 10.5 × 103/μL (normal range 3.3–9.0 × 103/
μL); red blood cells, 28.5 × 106/μL (4.3–5.7 × 106/μL);
hemoglobin, 9.2 g/dL (13.5–17.5 g/dL); total protein,
5.0 g/dL (6.7–8.3 g/dL); albumin, 1.5 g/dL (4.0–5.0 g/dL);
total bilirubin, 26.0 mg/dL (0.3–1.1 mg/dL); direct
* Correspondence: makoto@u-fukui.ac.jp
First Department of Surgery, School of Medicine, University of Fukui, 23
Shimoaiduki, Matsuoka, Eiheiji-cho, Fukui 910-1193, Japan
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Murakami et al. Surgical Case Reports  (2016) 2:141 
DOI 10.1186/s40792-016-0269-8
bilirubin, 17.0 mg/dL (0.1–0.5 mg/dL); aspartate amino-
transaminase, 91 IU/L (normal 10–40 IU/L); alanine
aminophosphatase, 90 IU/L (5–45 IU/L); aspartate trans-
ferase, 1560 IU/L (100–325 IU/L); and gamma-
glutamyltranspeptidase, 278 IU/L (7–80 IU/L). His
carbohydrate antigen 19-9 (CA19-9) was 40,635 U/mL
(0–37 U/mL), and carcinoembryonic antigen (CEA) was
10.4 ng/mL (0–5.0 ng/mL). Alpha fetoprotein levels were
within normal limits.
An abdominal computed tomography (CT) scan
revealed an enhanced mass that was approximately
2.5 cm in size located in the mid common bile duct
(CBD) and an enlarged regional node in the hepatoduo-
denal ligament (Fig. 1a). 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) revealed high accumu-
lation of FDG with a maximum standardized uptake
value (SUVmax) of 20.7 by the CBD tumor (Fig. 1b).
Endoscopic retrograde cholangiopancreatography
(ERCP) demonstrated severe intrahepatic bile duct
dilatation and a filling defect in the mid-CBD. The
tumor was involved with the cystic duct. After the ERCP,
endoscopic placement of a nasobiliary biliary drainage
catheter was performed (Fig. 2). The bile and brush
cytology performed at the same time revealed a few de-
generative atypical cells (class 3).
The patient underwent surgery with the presumed
diagnosis of bile duct cancer. The operative method was
extrahepatic bile duct resection with lymph node dissec-
tion and reconstruction with a Roux en Y hepaticojeju-
nostomy because of his advanced age and severe
pulmonary emphysema. The 18 regional lymph nodes
were resected. The right hepatic artery was fixed to the
tumor, and we performed a complicated resection. There
was evidence of local cancer invasion, but no signs of
distant metastasis or organ invasion were noted. The re-
section margins of the proximal and distal bile duct fro-
zen biopsy were tumor free. Peritoneal lavage cytology
during the operation was negative.
Macroscopically, the surgical specimen showed a light
gray invasive nodular tumor measuring 2.4 × 1.9 cm lo-
cated in the mid-CBD (Fig. 3a). The sectioned surface of
the resected specimen showed tumor invasion beyond
the bile duct serosa (Fig. 3b). There were no gallstones
in either the gallbladder or bile ducts.
On histopathological examination of the resected
specimen stained with hematoxylin and eosin, the tumor
was structured with two components (Fig. 4a). There
was no transitional area between the two components.
High cellularity components made up approximately
90% of the tumor and exhibited invasion throughout the
entire CBD wall with serosal penetration (Fig. 4b). The
other component was tubular adenocarcinoma, and it
occupied a small area of the tumor in the superficial
mucosal portion (Fig. 4c). In the LCNEC area, the tumor
was solid and cellular with necrosis inside. There was no
differentiation into duct structures. The tumor cells were
joined together, and the cells, nucleus, and cytoplasm
were relatively large (Fig. 4d). A high-power image of d
shows that the tumor cells were large idioblasts and the
nucleolus was clear. Each nucleus variant was strong,
and the heteromorphic nuclei division image was
obvious (Fig. 4e).
Fig. 1 CT (early phase) and FDG-PET findings. a CT showed an enhanced mass that was approximately 2.5 cm in size located in the mid-CBD
(arrow). b FDG-PET showed a high accumulation of FDG with a maximum standardized uptake value (SUVmax) of 20.7 in the CBD tumor (arrow)
Fig. 2 Cholangiopancreatography findings. Cholangiography
revealed severe intrahepatic bile duct dilatation and a filling defect
in the mid-CBD (arrow). The tumor involved with the cystic duct
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Immunohistochemical findings in the LCNEC compo-
nent indicated that the tumor cells were immunopositive
for neuroendocrine markers, including synaptophysin
and CD56, but were negative for chromogranin A and
neurospecific enolase (NSE) (Fig. 5a–c). Immunostaining
for Ki-67 showed a strong positive of 72% (Fig. 5d).
Immunohistochemical findings in the adenocarcinoma
component indicated that the tumor cells were not
immunopositive for neuroendocrine markers (Fig. 6a–c).
There were no transitional areas between the compo-
nents. Staining for Ki-67 showed mild positive at 27%
(Fig. 6d). Metastases from the LCNEC were noted in
Fig. 3 Formalin-fixed surgical specimen. a The surgical specimen showed a tumor measuring 2.4 × 1.9 cm located in the mid-CBD (arrow). b The
sectioned surface (at #1 and #2 of Fig. 1) of the resected specimen showed tumor invasion beyond the bile duct serosa
Fig. 4 Pathologic examination of the resected specimen stained with hematoxylin and eosin. a Loupe image of the tumor revealed invasion
throughout the entire CBD wall with serosal penetration. b Magnification of the part in the square in a. The tumor was structured with two
components (black and white arrows). There was no transitional area between the two components. c Intermediate-magnification image of the
part marked with a black arrow showed moderate differentiated adenocarcinoma. d The intermediate-magnification image of the part marked
with a white arrow shows LCNEC, which made up approximately 90% of the tumor. The tumor was solid and cellular with necrosis inside. The
tumor cells were joined together, and the cytoplasm was relatively large. e A high magnification of d shows that each nucleus variant was large
and the heteromorphic nuclei division image was obvious
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two of the 18 lymph nodes. The metastatic lymph nodes
were in contact with the tumor.
No postoperative complications occurred, and the
patient was discharged. His CEA and CA19-9 levels
normalized after the operation.
The patient had peritoneal metastases develop during the
early postoperative period, and a postoperative CT only
2.5 months later showed a lung metastasis and multiple
liver metastases occupying half of the liver. The patient died
3 months after surgery.
Discussion
In the World Health Organization classification, neuroen-
docrine neoplasms are classified into five general categor-
ies, including neuroendocrine tumor (NET), NEC, mixed
adenoneuroendocrine carcinoma (MANEC), goblet cell
Fig. 5 Immunohistochemical findings in the component of LCNEC. a Immunostaining for synaptophysin was partially positive. b Immunostaining
for chromogranin A was negative. c Immunostaining for CD56 was strongly positive in most of the LCNEC cells. d Immunostaining for Ki-67 was
strongly positive in 72% of the LCNEC cells
Fig. 6 Immunohistochemical findings in the component of adenocarcinoma. There were no immunopositive cells in the adenocarcinoma
component. a Immunostaining for synaptophysin was negative. b Immunostaining for chromogranin A was negative. c Immunostaining for CD56
was negative. d Immunostaining for Ki-67 showed diffused positivity in 27% of the adenocarcinoma cells
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carcinoid, and tubular carcinoid. In addition, NECs are
classified as either LCNEC or small-cell neuroendocrine
carcinoma (SCNEC) [1]. When each component is more
than 30% of the tumor, it is defined as MANEC.
The bile ducts are one of the rarest primary organs for
NET, accounting for only 0.2 to 2.0% of all such tumors
[2]. NEC arising in the extrahepatic bile duct includes
pure NEC, MANEC, and NEC with adenocarcinoma,
but only 27 cases have been described previously in the
literature [3–29] (Table 1). Of these, 19 cases were pure
NEC and eight cases were composite glandular–endo-
crine cell carcinoma of the extrahepatic bile ducts. Most
of these cases (82%) were SCNEC, and LCNEC was
extremely rare, only five cases. Sato et al. first reported
LCNEC with adenocarcinoma in the CBD in 2006 [16],
and thus, our case becomes the sixth report of LCNEC
arising in the extrahepatic bile duct.
Sasatomi (2013), Ninomiya (2013), and Park (2014)
reported cases of pure LCNEC in the CBD [26–28].
From what can be analyzed from the literature, the mean
tumor diameter was 3.5 cm (range 0.3–6.5 cm), median
survival time was 12.0 months (range 0.7–45 m), and
the 1-year survival rate was 32.6%. In 84% of cases,
radical resection was performed.
The pathological fact that normal bile duct mucosa
does not have neuroendocrine cells was cited as one of
the reasons why a primary NEC of the CBD is extremely
rare. Harada et al. examined 274 cases of biliary cancer
and reported that MANET was found in 4% of hepatic
hilar cholangiocarcinomas with hepatolithiasis, 10% of
Table 1 Reported cases of neuroendocrine carcinoma of the extrahepatic bile duct. Review of the literature
No. Author Age Sex Histology Location Size Treatment Prognosis
1 Sabanathan [3] 67 M SCNEC Bm 5 cm Palliative bypass and chemo. 6 m, alive
2 Van der Wal [4] 55 M SCNEC + Adenoca. Bm 4 cm Resection N.A.
3 Nishihara [5] 64 M SCNEC + Adenoca. Bh-Bs 1.9 cm Resection 8 m, alive
4 Yamamoto [6] 71 F SCNEC + Adenoca. Bh 6 cm Resection 8 m, dead
5 Kim [7] 64 M SCNEC + Adenoca. Bm 3 cm Resection 1 m, alive
6 Miyashita [8] 85 F SCNEC Bi 3 cm Palliative bypass 5 m, dead
7 Edakuni [9] 82 F SCNEC + Adenoca. Bm 6 cm Resection 45 m, alive
8 Kuraoka [10] 75 M SCNEC Bi 4.5 cm Resection 5 m, alive
9 Hazama [11] 60 M SCNEC CBD 0.3 cm NAC and resection 12 m, dead
10 Arakura [12] 70 F SCNEC Bm 3 cm Resection and chemo. 14 m, dead
11 Park [13] 60 F SCNEC Bs-Bm 3 cm Resection 5 m, dead
12 Thomas [14] 54 M SCNEC Bh-Bm N.A. Resection 6 m, alive
13 Kaiho [15] 66 F SCNEC + Adenoca. Bm 3.5 cm Resection and chemo. 8 m, dead
14 Sato [16] 68 M LCNEC + Adenoca. Bi 2 cm Resection and chemo. 3 m, dead
15 Viana Miguel [17] 76 M SCNEC Bm N.A. Resection, chemo., and irradiation 5 m, alive
16 Jeon [18] 65 M SCNEC Bs-Bm 2 cm Resection and chemo. 12 m, dead
17 Nakai [19] 32 M SCNEC CBD N.A. N.A. N.A. (autopsy)
18 Arakura [20] 75 M SCNEC Bh-Bs 6.5 cm Chemo. and irradiation 10 m, dead
19 Hosonuma [21] 69 F SCNEC Bs-Bm 3 cm Biliary drainage 2 m, alive
20 Okamura [22] 62 M SCNEC Bm 3 cm NAC, resection, and irradiation 20 m, dead
21 Yamaguchi [23] 77 F NEC Bi N.A. Resection and chemo. 27 m, alive
22 Demoreuil [24] 73 M LCNEC + Adenoca. Bh-Bs 3 cm Resection and chemo. 12 m, dead
23 Cho [25] 59 F SCNEC Bm 3 cm Resection 6 m, dead
24 Sasatomi [26] 76 M LCNEC Bh-Bs 5 cm Resection 21 days, dead
25 Ninomiya [27] 75 F LCNEC Bm 3 cm Resection 14 m, alive
26 Park [28] 75 F LCNEC Bm 2.7 cm Resection and chemo. 12 m, dead
27 Kihara [29] 70 F SCNEC Bh 5 cm Resection and chemo. 10 m, alive
28 Current report 79 M LCNEC + Adenoca. Pm 2.9 cm Resection 3 m, dead
NEC neuroendocrine carcinoma, NAC neoadjuvant chemotherapy, Adenoca. adenocarcinoma, CBD common bile duct, Bh hilar bile duct, Bs superior portion of
common bile duct, Bm mid-portion of bile duct, Bi inferior portion of bile duct, chemo. chemotherapy, N.A. not available
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gallbladder cancers, and 4% of extrahepatic cholangio-
carcinomas [30]. The authors of this report expressed
the opinion that normal adenocarcinoma developed
during a process of growth and dedifferentiation to
endocrine cells. Albores et al. reported that neuroendo-
crine cells could be detected at sites of intestinal meta-
plasia induced by chronic inflammation due to
cholelithiasis and congenital anomalies, which might be
the initial step in the development of neuroendocrine
tumors of the CBD [31]. The process suggested this
report was one reason why pure NET and NEC devel-
oped. Although pure NET cases without dysplastic
intestinal-type epithelium exist, they seem to follow a
different developmental process.
LCNEC of the CBD is a poorly differentiated and rare
tumor that exhibits high-grade NET with aggressive be-
havior and has a strong tendency to develop early lymph
node and distant metastases. The survival duration of
previously reported cases of LCNEC of the CBD ranged
from only 21 days to 12 months after surgery (Table 1).
In our case, the recurrence was noted 2.5 months after
surgery, and the patient died 3 weeks after the recur-
rence. The prognosis of LCNEC is extremely poor in
comparison with adenocarcinoma of the same clinical
stage, even if we can resect the tumor radically.
In this case, we chose to perform extrahepatic bile
duct resection, which is not commonly used. In cases of
extrahepatic bile duct cancer with obstruction of the
cystic duct, we usually perform subtotal stomach-
preserving pancreatoduodenectomy because of metasta-
sis of lymph nodes around the head of the pancreas and
direct invasion to the pancreatic parenchyma. Because
the patient was 80 years old and had progressive demen-
tia and severe pulmonary emphysema, once the
resection margin of the distal CBD frozen biopsy was
tumor free, with the consent of his family, we decided to
defer pancreatoduodenectomy. We do not believe that
this reduction surgery caused early postoperative liver
metastasis.
Adjuvant chemotherapy in three cases of LCNEC of
the CBD was reported previously [16, 24, 27], and these
patients survived 3 to 12 months. Yamaguchi et al.
reported that adjuvant chemotherapy with gemcitabine
could not suppress the recurrence, but hepatic artery
infusion with CPT-11 (40 mg/kg body weight) and
CDDP (20 mg/kg body weight) every 2 weeks remark-
ably decreased tumor markers and the size of both
lymph nodes and liver tumors [23].
At present, it is controversial whether a combination
of chemotherapy and radiotherapy is more effective than
resection alone [17, 22]. In this case, we could not pro-
vide adjuvant chemotherapy because of the general poor
condition of the patient. Because peritoneal, lung, and
liver metastases developed during the early postoperative
period, it was hard to attempt any adjuvant chemother-
apy in LCNEC. If a diagnosis of LCNEC of the CBD was
possible preoperatively, we could consider neoadjuvant
multimodal treatments before resection to improve the
prognosis [11, 21, 32]. However, it was difficult to diag-
nose NEC of the CBD preoperatively, because there is
no difference between adenocarcinoma and NEC in
symptoms, blood tests, and imaging studies. In most
cases, the definitive diagnosis was established by histo-
pathological and immunohistochemical analysis of the
surgical specimen. Only three cases were diagnosed pre-
operatively by percutaneous transhepatic cholangioscopy
with biopsy [11], ERCP with brushing [14], and endo-
scopic ultrasonography-guided fine-needle aspiration
biopsy [12]. In our case, we were not able to detect
malignant cells by brush cytology of the bile duct. The
submucosal location of NEC causes a large number of
false-negative results on brush biopsy, making it difficult
to achieve a correct preoperative diagnosis.
In our case, CA19-9 was elevated to a high level
(40,635 U/mL), but it was thought that the abnormal
value was caused by chronic cholestasis and cholangitis.
The patient’s postoperative values of CA19-9 reduced to
a normal level immediately and did not correlate with
the cancer recurrence.
Cho et al. suggested that NEC of the CBD should be
considered in differential diagnosis of causes of obstruct-
ive jaundice and hemobilia [25]. We examined the intra-
ductal ultrasonography of the CBD in our case and
detected a large quantity of clots in the lower bile duct.
It was thought that this appearance was due to LCNEC,
which was often associated with necrosis. The Ki-67
index in the LCNEC component was higher than in the
adenocarcinoma component (72 vs. 27%), and probably
reflecting this difference, the SUVmax of the LCNEC
was high (20.7) on the FDG-PET. When the SUVmax
reaches an abnormally high level, it seems reasonable to
suspect a different type of carcinoma.
Conclusions
In summary, we report a case of LCNEC of the CBD.
This disease is extremely rare and has an aggressive
malignant potential, including invasiveness and metasta-
sis. There are no effective treatments, including resec-
tion. Accumulation of more cases and further studies of
multimodal treatment are required to improve the
prognosis of patients with this disease.
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